Oligonucleotides, nucleic acid polymers capable of modulating gene expression, are a key component of many cell and gene therapies. Advances in their design and production have served to facilitate the success of many new drugs that possess greater stability, specificity, and efficacy by targeting faults in genetic code to address the root cause of a disease.
The process of manufacturing an oligonucleotide relies on consistency, as each step may be repeated dozens of times to achieve the desired molecule. Employing an oligonucleotide synthesizer serves to automate this process, resulting in greater reliability and reproducibility. Choosing the right oligosynthesizer for a process can be challenging, particularly as a program scales. While there are always individual considerations that impact this assessment, there are also many baseline optimizations that organizations can pursue that, coupled with tailored solutions, achieve the necessary flexibility and efficiency to optimize these processes.
In a recent webinar, experts from Asahi Kasei Bioprocess, an equipment solutions provider with expertise in fluid management technology, explored how choosing an oligosynthesizer that has been sized and configured correctly for an asset’s scale-up can minimize waste and create the efficiency needed to achieve commercial success.